SpotDraft, the CLM platform that helps in-house legal teams manage their contract ecosystems, has raised $54 million in ...

The daughter of a key architect of Project 2025 benefitted from a life-changing drug — which was created with the help of the ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

A federal judge on Tuesday ordered U.S. health agencies to restore websites that they abruptly took offline in response to an executive order by President Donald Trump telling them to scrub websites ...

Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $467.00.

State law has tried to bring more transparency to issues at North Carolina group homes that house adults living with mental ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...